

ROCOG II

Sustaining a culture of clinical trials





Dwight E. Heron, MD Principal Investigator

Barb Klewien, BS Project Director

Our Team

- Dwight E. Heron, MD Pl
- Heather Jones, MD Co-investigator
- Susan Rakfal, MD Co-investigator
- Barbara Klewien, BS Project Director
- Michele Wagner, RN Clinical Research Coordinator

Summary of ROCOG I

- No cost extension pending
 - Closeout in progress
 - Trials accruals: 118
 - Navigation programs sustained in 3 communities
 - TELESYNERGY™ fully integrated in 3 sites
 - Tumor boards (New Castle/McKeesport)
 - Mentor communication (McKeesport)
 - Patient consultation (Somerset)
 - Outreach to nearly 47,000 individuals
 - Publications 14 papers in peer reviewed journals
 - Presentations 21 oral & poster

Plans for ROCOG II

- Patient-centered informed decision coach implementation
- Implement population appropriate trials
- Implement screening documentation tool
- Sustainability plans beyond ROCOG II

Typical UPMC McKeesport Patient Screened for Trials

- Age 65 or older (63%)
- Caucasian (80%)
- African American (17%)
- Not accrued due to:
 - No available trial (54%)
 - Late stage disease at presentation prevalent in community
 - Clinical trial(s) criteria too restrictive (22%)

Informed Decision Coach Study

- Designed as clinical trial
 - Pending IRB approval
 - Evaluates
 - Patient satisfaction with decision
 - Will education (disease specific) increase accrual to clinical trials
 - Difference between satisfaction with decision in clinical trial vs non clinical trial participants

Addressing Population-Appropriate Trials

- Investigator-initiated breast trial
 - Hypofractionated Radiation Therapy for the Elderly Breast Cancer (H. Jones, PI)
- Ongoing assessment of available trials
- Evaluation of most appropriate & available trials

Accruals by Disease Site

Disease Site	Trials Open	% open trials	Patients Accrued	% Patients Accrued
Brain	4	8%	14	13%
Breast	11	23%	32	30%
GI	10	21%	20	19%
Head & Neck	8	17%	15	14%
Lung/Thoracic	12	25%	21	20%
Prostate/Urolog	3	6%	5	5%
	48	100%	107	100%

